MindBio Therapeutics Develops AI Voice-Based Intoxication Detection for Real-Time Diagnostics

MindBio Therapeutics Corp. (CSE: MBIO; Frankfurt: WF6; OTCQB: MBQIF) is advancing an AI-driven voice analysis platform designed to detect drug and alcohol intoxication in real time, as the real-time diagnostics market expands. The company's platform leverages speech as a diagnostic biomarker to enable faster, scalable, and noninvasive impairment detection, addressing limitations of traditional testing methods.

By using voice as a biomarker, MindBio aims to differentiate itself in the evolving AI healthcare landscape, which includes companies such as HeartFlow Inc. (NASDAQ: HTFL), Recursion Pharmaceuticals Inc. (NASDAQ: RXRX), Tempus AI Inc. (NASDAQ: TEM), and Butterfly Network Inc. (NYSE: BFLY). The company is targeting commercial opportunities in workplace compliance, telehealth, and consumer health applications.

MindBio's AI prediction model uses over 50 million data points to predict alcohol intoxication with high accuracy using the human voice. The company is developing an enterprise platform, including Edge-AI kiosks that integrate bespoke hardware and software for detecting drug and alcohol intoxication in environments such as mining, aviation, construction, and law enforcement.

For more information, view the full press release at https://ibn.fm/BZOb2. The latest news and updates relating to MBQIF are available in the company’s newsroom at https://ibn.fm/MBQIF.